LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki President and Chief Operating Officer Sunovion Pharmaceuticals Inc.
Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA � Overall market growth is stable and unmet needs remain • Efficacy is key reason to prescribe • High switch and discontinuation rates � Strong clinical profile and competitive LATUDA label • Inclusion of olanzapine arm in efficacy and weight data sections (as an active control to assess assay sensitivity) • 4 positive efficacy studies • Two dose options, once-daily • 2,000+ safety database • No QTc warning � 336 dedicated and experienced Sales Force • Majority have previously sold at least 1 other atypical antipsychotic � Customer-centric commercial organization • Focus on engaging psychiatrists through multimodal approach • Competitive pricing and reimbursement strategies 1
Atypical Antipsychotic Market Growing at 3% $15.8BN Market Growth in the Atypical Antipsychotic Category Is Being Driven by Use in Bipolar Disorder and Depression 60,000 50MM 49MM 47MM 50,000 2,373 2,372 DX CAGR 2,120 6,522 6,644 5,847 TRx (000s) 40,000 Anxiety 6% 8,373 8,647 9,121 Depression 6% 30,000 All others -4% 15,045 14,735 14,169 Schizophrenia 3% 20,000 Bipolar Disorder 6% 10,000 17,202 16,237 15,324 Market 3% 0 MAT Nov 2008 MAT Nov 2009 MAT Nov 2010 Bipolar Disorder Schizophrenia All others Depression Anxiety Source: Derived from IMS NPA Data, and SDI PDDA 2
Monthly Antipsychotic Market TRx Share Trend Established Market 40% 35% 30% Seroquel Risperidone 25% TRx Share Abilify 20% Zyprexa 15% Geodon 10% Seroquel XR 5% Saphris Fanapt 0% D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N 2007 2008 2009 2010 Source: IMS NPA. The Atypical antipsychotic market is defined as ANTIPSYCHOTICS, OTHERS (USC 64190), excluding Haldol, Loxapin, Moban, Navane, Orap, and Thiothixene, etc. 3
Psychiatrists Need New Treatments that Provide a Combination of Strong Efficacy and Tolerability Effective in Treating 80 Positive Symptoms Efficacy Effectively controls 53 agitation/aggression Safe for Safety 49 Long-Term Therapy Tolerability Well Tolerated 66 Good patient 49 compliance Does Not Cause 39 Significant Weight Gain Effective in Treating 39 Negative Symptoms Higher Importance Low Incidence of Medium Importance 37 Extrapyramidal Side Effects 0 25 50 75 100 Percent of Psychiatrists Source: GfK, 2009 Schizophrenia Physician Study 4
No Single Preferred Agent for Treatment of Schizophrenia All Uses Schizophrenia Uses MAT Sept 2010 MAT Sept 2010 Invega Sustenna Risperdal 0.2% Saphris Risperdal FANAPT Invega Invega Sustenna 0.5% 0.4% Consta 0.1% Invega Seroquel XR 3.2% 0.8% Fanapt 0.9% Saphris 1.8%Clozapine 3.8% 0.2% 0.3% 2.6% Risperdal Consta Seroquel XR 4.1% Risperidone 5.4% Geodon Seroquel 21.2% Geodon 6.7% 29.5% 8.4% Zyprexa Clozapine 10.3% 10.0% Seroquel 18.0% Abilify Abilify Risperidone 13.5% 19.8% Zyprexa 22.1% 16.5% Source: Wolters Kluwer Source Lx Based on Market Research 5
High Discontinuation Rates Create Opportunity for LATUDA � CATIE Reinforced Need for New Treatment Options • 74% of patients discontinued the study medication before 18 months � Patients dissatisfied with current options • Continue to experience breakthrough symptoms • Discontinue due to adverse “ Two drugs, olanzapine and clozapine, “ Two drugs, olanzapine and clozapine, events, lack of efficacy appear to be more effective than other appear to be more effective than other agents. However, both drugs induce a agents. However, both drugs induce a • Likely to have tried multiple significantly greater number of serious side significantly greater number of serious side medications effects. Even the most feared side effect… effects. Even the most feared side effect… tardive dyskinesia, seems less troubling tardive dyskinesia, seems less troubling than potentially fatal metabolic problems.” than potentially fatal metabolic problems.” – Robert Freedman, MD, NEJM – Robert Freedman, MD, NEJM 6
Leverage Strong Clinical Profile and Positive Label � Opportunity to improve value proposition vs. current atypical antipsychotics • Once-daily with food • The recommended starting dose is the therapeutic dose – 40 mg • LATUDA offers proven efficacy with positive cardiometabolic profile • No QTc warning � Differentiate from current atypical antipsychotics that offer partial efficacy/response • 4 positive efficacy studies included in label • Efficacy confirmed for both doses in 2 studies each 7
Psychiatrists Are Key Driver for Launch Schizophrenia Treatment by Specialty � A large and stable market with ~2 million patients with PCP & Others, Schizophrenia in the US Neuro 3% 0.5% � Our current target audience ~22,000 psychiatrists � 336 Sales Force will cover target audience and will be able to attain competitive share of voice by focusing on these Psych, specialists 97% Source: SDI PDDA 8
Leverage Dedicated and Experienced Sales Force Ready to Deliver on the Potential of LATUDA � Sales force: 336 � Hospital sales force: 70 � Extensive experience selling in the atypical antipsychotic arena � Dedicated and qualified Area Medical Specialists team � Managed care and Government Affairs team with strong category knowledge 9
Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA � Unsatisfied physician and patient population as evidenced by high switch rates creates opportunity for LATUDA � LATUDA has a strong clinical profile and competitive label � Dedicated and experienced Sales Force ready to compete � Focused on key access issues to ensure success 10
Disclaimer Regarding Forward-looking Statements The statements made in this presentation material are forward-looking statements based on management’s assumptions and beliefs in light of information available up to the day of announcement, and involve both known and unknown risks and uncertainties. Actual financial results may differ materially from those presented in this document, being dependent on a number of factors. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. 11
Recommend
More recommend
